NATCO PHARMA Fact Sheet, NATCO PHARMA Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA Fact Sheet    (NTPH)


Our FREE Guide: Small Caps That Will Race Ahead of the Sensex


Here is the latest financial fact sheet of NATCO PHARMA. For more details, see the NATCO PHARMA quarterly results and NATCO PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

NATCO PHARMA Price History

Price Rs 679.9
Mkt Cap Rs m 124,121
Vol '000 10.5
P/E X 45.4
P/CF X 22.2
EPS (TTM) Rs 15.0
1 Day % 0.8
No. of shares m 182.56
1 Week % -3.0
1 Month % -13.8
1 Year % -36.6
52 week H/L Rs 1,188.1/645.5
As on May 27, 2022 (Close)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NATCO PHARMA Financials

No. of Mths
Year Ending
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
12
Mar-20
*
12
Mar-21
*
5-Yr Chart
Click to enlarge
NATCO PHARMA EQUITY SHARE DATA
High Rs8501,080849738995 
Low Rs411671557450492 
Sales per share (Unadj.) Rs113.3117.5114.6105.2112.5 
Earnings per share (Unadj.) Rs27.837.735.225.224.3 
Diluted earnings per shareRs26.638.135.225.124.2 
Cash flow per share (Unadj.) Rs30.941.339.630.630.7 
Dividends per share (Unadj.) Rs6.758.256.256.755.25 
Adj. dividends per shareRs6.458.346.266.735.24 
Avg Dividend yield %1.10.90.91.10.7 
Book value per share (Unadj.) Rs93.7165.2189.2206.0225.1 
Adj. book value per shareRs89.5167.0189.4205.4224.8 
Shares outstanding (eoy) m174.31184.49182.75182.07182.34 
Bonus / Rights / Conversions  00000 
Price / Sales ratio x5.67.56.15.66.6 
Avg P/E ratio x22.723.220.023.630.6 
P/CF ratio (eoy) x20.421.217.819.424.2 
Price / Book Value ratio x6.75.33.72.93.3 
Dividend payout %24.321.917.826.821.6 
Avg Mkt Cap Rs m109,862161,547128,471108,130135,564 
No. of employees `000NANANANANA 
Total wages/salary Rs m2,4323,2563,5593,7504,149 
Avg. sales/employee Rs Th00000 
Avg. wages/employee Rs Th00000 
Avg. net profit/employee Rs Th00000 
NATCO PHARMA INCOME DATA
Net Sales Rs m19,75421,67620,94519,15020,521 
Other income Rs m1394041,3021,0741,060 
Total revenues Rs m19,89322,08022,24720,22421,581 
Gross profit Rs m6,8349,2847,9485,8266,038 
Depreciation Rs m5446628109981,169 
Interest Rs m185154193215133 
Profit before tax Rs m6,2448,8728,2475,6875,796 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m1,3951,9201,8231,1061,372 
Profit after tax Rs m4,8496,9526,4244,5814,424 
Gross profit margin %34.642.837.930.429.4 
Effective tax rate %22.321.622.119.423.7 
Net profit margin %24.532.130.723.921.6 
NATCO PHARMA BALANCE SHEET DATA
Current assets Rs m10,87321,30723,47223,25623,373 
Current liabilities Rs m6,2655,9207,2876,8535,256 
Net working cap to sales %23.371.077.385.788.3 
Current ratio x1.73.63.23.44.4 
Inventory Days Days1726423663 
Debtors Days Days881078810573 
Net fixed assets Rs m12,30315,84419,55922,62224,546 
Share capital Rs m349369365364365 
"Free" reserves Rs m15,99030,11434,21737,13640,676 
Net worth Rs m16,33930,48334,58237,50041,041 
Long term debt Rs m00099 
Total assets Rs m23,17637,15143,03145,87847,919 
Interest coverage x34.858.643.727.544.6 
Debt to equity ratio x00000 
Sales to assets ratio x0.90.60.50.40.4 
Return on assets %21.719.115.410.59.5 
Return on equity %29.722.818.612.210.8 
Return on capital %39.329.624.415.714.4 
Exports to sales %00000 
Imports to sales %11.413.714.09.510.9 
Exports (fob) Rs m00000 
Imports (cif) Rs m2,2542,9782,9391,8182,231 
Fx inflow Rs m6,79310,32211,5368,73611,194 
Fx outflow Rs m2,2542,9782,9391,8182,231 
Net fx Rs m4,5387,3438,5976,9188,963 
NATCO PHARMA CASH FLOW
From Operations Rs m 3,458 4,636 6,688 4,173 2,988 
From Investments Rs m -2,994 -11,155 -6,122 -1,670 -1,033 
From Financial Activity Rs m -477 6,509 -509 -2,508 -1,857 
Net Cashflow Rs m -7 -18 66 -85 60 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 48.8%
Institution 28.1%
Non-Institution 23.1%
Total 100.0%
Free Float 51.2%
Pledged promoter holdings 0.0%
Shareholding as on Mar 2022
 

Company Information

Regd Off Natco House, Road No 2, Banjara Hills, Hyderabad - 500003
E-mail investors@natcopharma.co.in Web www.natcopharma.co.in
Tel 040-23547532 Fax 040-23548243
Sector PHARMACEUTICALS Group Natco
Tr Agent Venture Capital & Corporate Investments Ltd, 12-10-167, MIG- 167, Bharat Nagar Colony
Auditor Walker, Chandiok & Co.
CHM: G S Murthy COMP SEC: Chekuri Venkat Ramesh YEAR OF INC: 1981 BSE CODE: 524816 FV (Rs): 2 DIV YIELD (%): 0.8

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    

Compare NATCO PHARMA With:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    




Today's Market

Sensex Rallies 632 Points, Nifty Ends Above 16,350; Banking & IT Stocks Witness Buying(Closing)

Indian share markets rose today as easing bets about aggressive interest rate hikes by central banks lifted sentiment.

Views on news

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

Nifty Pharma Index - Bulls are Losing the Ground (Views On News)

Mar 16, 2022

For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far... (Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022 (Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022 (Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look... (Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better? (Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NATCO PHARMA

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS